Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The 5-fluorouracil (5-FU)-based chemotherapy regimen is a primary strategy for treating pancreatic cancer (PC). However, challenges related to 5-FU resistance persist. Investigating the mechanisms of 5-FU resistance and identifying a clinically viable therapeutic strategy are crucial for improving the prognosis of PC. Here, through clinical samples analysis, we found that the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme in mevalonate metabolism, is negatively correlated with the efficacy of 5-FU treatment. There is a significant correlation between HMGCR and the pyroptosis marker gasdermin D (GSDMD), and the HMGCR inhibitor simvastatin can significantly inhibit the activation of pyroptosis signaling. The exogenous addition of geranylgeranyl pyrophosphate (GGPP), a key metabolite of the mevalonate pathway, can significantly reduce sensitivity to 5-FU, and simvastatin combined with 5-FU demonstrates a strong synergistic effect. Furthermore, in organoid models and genetically engineered mice with spontaneous PC, the combination of simvastatin and 5-FU significantly inhibits tumor growth. In conclusion, our study reveals the critical role of the mevalonate pathway in 5-FU resistance and proposes a clinically feasible combination therapy strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HMGCR expression may also be relevant, given the inverse association with 5-FU sensitivity”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the HMGCR expression is negatively correlated with PDAC sensitivity to 5-fluorouracil (5-FU)”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“the association of simvastatin to 5-FU produces a strong synergistic effect in MIA PaCa-2 line”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“the addition of GGPP, a mevalonate pathway product with a role in prenylation, decreases the 5-FU sensitivity”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · cited 1×
“Despite recent advances in pancreatic cancer (PC) treatment, it remains a significant challenge, with a 5-year survival rate of less than 10% [1, 2].”
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“…(5-FU) is the cornerstone of the therapeutic protocol, and 5-FU-based FOLFIRINOX is recommended for patients with PC after surgery [3] 0.5-FU, a cell cycle-specific uracil analog, interacts with DNA,RNA, or both, leading to its accumulation in cells, and causing tumor cell damage and death [4].”
InfluentialPyroptosis: A new frontier in cancer
Fang, Y., Tian, S., Pan, Y., Li, W., Wang, Q., Tang, Y., Yu, T., Wu, X., Shi, Y., Ma, P., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109595 · Cited by 1,049
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Huang, B., Song, B.-L., & Xu, C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0174-0 · Cited by 921 · cited 1×
“The mevalonate pathway, a critical pathway for cholesterol synthesis, plays a significant role in tumor progression when abnormally activated [14].”
Pyroptosis in inflammatory diseases and cancer
Rao, Z., Zhu, Y., Yang, P., Chen, Z., Xia, Y., Qiao, C., Liu, W., Deng, H., Li, J., Ning, P., et al. (2022) · Theranostics · doi:10.7150/thno.71086 · Cited by 800
Self-citationSethy, C., & Kundu, C. N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111285 · Cited by 539 · cited 1×
“However, due to the low stability of 5-FU in cells and the susceptibility to drug resistance, only a minority of patients benefit from FOLFIRINOX [7–9].”
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448 · cited 1×
“Despite recent advances in pancreatic cancer (PC) treatment, it remains a significant challenge, with a 5-year survival rate of less than 10% [1, 2].”
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417 · cited 3×
“Simvastatin, in addition to inhibiting cholesterol synthesis, can also target HMGCR and inhibit tumor progression by reducing GGPP and blocking protein prenylation [18, 26, 27].”
Cotte, A. K., Aires, V., Fredon, M., Limagne, E., Derangère, V., Thibaudin, M., Humblin, E., Scagliarini, A., de Barros, J.-P. P., Hillon, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02732-5 · Cited by 359 · cited 1×
“Additionally, the accumulation of lipid droplets and the overexpression of the nuclear protein sterol-regulatory element-binding protein-1 impede the anticancer effect of 5-FU [12, 13].”
Conroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., Mitry, E., Biagi, J. J., Evesque, L., Artru, P., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3829 · Cited by 344
Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., Sripadam, R., Mukherjee, S., Soonawalla, Z., Wadsley, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00348-x · Cited by 337
Self-citationNovel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents
Thurnher, M., Nussbaumer, O., & Gruenbacher, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0489 · Cited by 224 · cited 1×
“Simvastatin, in addition to inhibiting cholesterol synthesis, can also target HMGCR and inhibit tumor progression by reducing GGPP and blocking protein prenylation [18, 26, 27].”
Gasdermin-B Promotes Invasion and Metastasis in Breast Cancer Cells
Hergueta-Redondo, M., Sarrió, D., Molina-Crespo, Á., Megias, D., Mota, A., Rojo-Sebastian, A., García-Sanz, P., Morales, S., Abril, S., Cano, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090099 · Cited by 201 · cited 1×
“Additionally, there are no reports on the roles of GSDMA and GSDMB in pancreatic cancer, although they are known to promote tumor growth in other cancers [34–36].”
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology
Göbel, A., Rauner, M., Hofbauer, L. C., & Rachner, T. D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188351 · Cited by 164 · cited 1×
“The mevalonate pathway is the central pathway for cholesterol synthesis, and its aberrant activation is a hallmark of tumorigenesis [22].”
Autophagy, Pyroptosis, and Ferroptosis: New Regulatory Mechanisms for Atherosclerosis
Lin, L., Zhang, M.-X., Zhang, L., Zhang, D., Li, C., & Li, Y.-L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.809955 · Cited by 164 · cited 1×
“Pyroptosis, a proinflammatory form of regulated cell death, is distinct from autophagy and ferroptosis [28].”
USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway
He, H., Yi, L., Zhang, B., Yan, B., Xiao, M., Ren, J., Zi, D., Zhu, L. W., Zhong, Z., Zhao, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.54442 · Cited by 127
Jiang, X., Ma, Y., Wang, T., Zhou, H., Wang, K., Shi, W., Qin, L., Guan, J., Li, L., Long, B., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.025 · Cited by 126
Self-citationYu, Z., Jiang, X., Qin, L., Deng, H., Wang, J., Ren, W., Li, H., Zhao, L., Liu, H., Yan, H., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01572-w · Cited by 117
Self-citationAhn, K. S., Sethi, G., & Aggarwal, B. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.010 · Cited by 114
Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis
Zhou, W., Liu, H., Yuan, Z., Zundell, J. A., Towers, M., Lin, J., Lombardi, S., Nie, H., Murphy, B., Yang, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.002 · Cited by 109 · cited 3×
“According to the study, simvastatin inhibits tumor progression by targeting the mevalonate pathway and inducing pyroptosis [17].”
Recent studies of 5-fluorouracil resistance in pancreatic cancer
Wang, W., Yang, Y., Zhao, Y.-P., Zhang, T.-P., Liao, Q., & Shu, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15682 · Cited by 109
Klein-Brill, A., Amar-Farkash, S., Lawrence, G., Collisson, E. A., & Aran, D. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.16199 · Cited by 93 · cited 1×
“As a frontline treatment for PC, the FOLFIRINOX regimen demonstrates a longer median survival time compared to the treatment regimen combining gemcitabine with albumin-bound paclitaxel [21].”
Stine, J. E., Guo, H., Sheng, X., Han, X., Schointuch, M. N., Gilliam, T. P., Gehrig, P. A., Zhou, C., & Bae-Jump, V. L. (2016) · Oncotarget · doi:10.18632/oncotarget.5834 · Cited by 92 · cited 1×
“Simvastatin, in addition to inhibiting cholesterol synthesis, can also target HMGCR and inhibit tumor progression by reducing GGPP and blocking protein prenylation [18, 26, 27].”
Waller, D. D., Park, J., & Tsantrizos, Y. S. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1568964 · Cited by 86
Lee, J., Jung, K. H., Park, Y. S., Ahn, J. B., Shin, S. J., Im, S.-A., Oh, D. Y., Shin, D. B., Kim, T. W., Lee, N., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0913-5 · Cited by 77 · cited 1×
“Thirdly, through literature review, we found that there are additional mechanisms by which simvastatin enhances 5-FU [37–39].”
Gabriel, A. N. A., Jiao, Q., Umwali, Y., Yang, X., Al-Ameri, S. A. A.-E., Du, L., Wang, Y., & Wang, C. (2019) · Pancreatology · doi:10.1016/j.pan.2019.11.006 · Cited by 75
Yan, C., Niu, Y., Li, F., Zhao, W., & Ma, L. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03632-z · Cited by 73
Li, S., Ming, Y., Xu, H., Zhang, X., Mao, T., Quan, M., Ma, J., Wang, Y., Ge, W., Wang, Y., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216206 · Cited by 71
Lv, J., Liu, Y., Mo, S., Zhou, Y., Chen, F., Cheng, F., Li, C., Saimi, D., Liu, M., Zhang, H., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00857-4 · Cited by 67 · cited 1×
“Recent research indicates that GSDMC and GSDME play a facilitating role in the progression of pancreatic cancer [30–33].”
Gbelcová, H., Rimpelová, S., Knejzlík, Z., Šáchová, J., Kolář, M., Strnad, H., Repiská, V., D’Acunto, W. C., Ruml, T., & Vítek, L. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0641-0 · Cited by 37
Haney, S. L., Varney, M. L., Chhonker, Y. S., Shin, S. C., Mehla, K., Crawford, A. J., Smith, H. J., Smith, L. M., Murry, D. J., Hollingsworth, M. A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0794-6 · Cited by 37 · cited 1×
“GGPP, as a subsequent product of the mevalonate pathway, also promotes tumor progression through its abnormal accumulation in PC [24, 25].”
Lupuţ, L., Sesărman, A., Porfire, A. S., Achim, M., Muntean, D. M., Casian, T., Pătraș, L., Rauca, V. F., Drotar, D. M., Stejerean‐Todoran, I., et al. (2020) · Cancer Science · doi:10.1111/cas.14312 · Cited by 31
Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil
Yang, H., Xie, S., Liang, B., Tang, Q., Liu, H., Wang, D., & Huang, G. (2021) · Journal of Cancer · doi:10.7150/jca.58846 · Cited by 24
Öman, M., Wettergren, Y., Odin, E., Westermark, S., Naredi, P. L. J., Hemmingsson, O., & Taflin, H. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04318-x · Cited by 22 · cited 1×
“Therefore, 5-FU plays an indispensable role in the treatment process of PC [5, 6].”
Wu, R., Li, J., Aicher, A., Jiang, K., Tondi, S., Dong, S. L., Zheng, Q., Tang, S., Chen, M., Guo, Z., et al. (2024) · Advanced Science · doi:10.1002/advs.202308990 · Cited by 21
Cao, J., Sun, X., Zhang, X., & Chen, D. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.06.014 · Cited by 20
In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway
Haney, S. L., Varney, M. L., Chhonker, Y. S., Talmon, G. A., Smith, L. M., Murry, D. J., & Holstein, S. A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105528 · Cited by 18 · cited 1×
“GGPP, as a subsequent product of the mevalonate pathway, also promotes tumor progression through its abnormal accumulation in PC [24, 25].”
Timosaponin A3 Inhibits Palmitate and Stearate through Suppression of SREBP-1 in Pancreatic Cancer
Kim, Y., Jee, W., An, E.-J., Ko, H. M., Jung, J. H., Na, Y., & Jang, H.-J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050945 · Cited by 17 · cited 1×
“HMGCR can promote tumor proliferation to some extent [23].”
SREBP1 promotes 5-FU resistance in colorectal cancer cells by inhibiting the expression of caspase7.
Gao, Y., Zhao, Q., Mu, X., Zhu, H., Liu, B., Yao, B., Liu, X., Xue, W.-H., Wang, B., & Liu, S. (2019) · Europe PMC (PubMed Central) · Cited by 16
Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer.
Klein, B., Sadikov, E., Mishaeli, M., Levin, I., & Figer, A. (2000) · Oncology Reports · doi:10.3892/or.7.4.875 · Cited by 15 · cited 1×
“Therefore, 5-FU plays an indispensable role in the treatment process of PC [5, 6].”
GSDMA at the crossroads between pyroptosis and tumor immune evasion in glioma
Zhang, R., Song, Q., Lin, X., Du, B., Geng, D., & Gao, D. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149181 · Cited by 12 · cited 1×
“Additionally, there are no reports on the roles of GSDMA and GSDMB in pancreatic cancer, although they are known to promote tumor growth in other cancers [34–36].”
Fu, X., & Luo, F. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23487 · Cited by 1
Cited by
Duttenhefner, J. N., & Reindl, K. M. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.06.004 · Cited by 6
“…highlight statin-mediated induction of cellular stress responses, including TME modulation 96 – 99 ] and triggering cellular processes such as autophagy, 100 – 102 ferroptosis, 67,103 ] and pyroptosis, 71 as well as unfolded protein responses linked to enhanced immunogenicity in KRAS mutant tumors.”
Yousaf, S., Ahmed, D. S., Arshad, M., Mammadova, K., Khokhar, A. M., Fawy, K. F., & Rafeeq, H. (2026) · Medical Oncology · doi:10.1007/s12032-026-03239-0 · Cited by 3
Lagunas‐Rangel, F. A. (2026) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100261447016 · Cited by 1
“Several studies have reported synergistic effects when statins are combined with conventional chemotherapeutic agents, such as 5-fl uorouracil (Xing et al., 2024), doxorubicin (Buranrat et al., 2017), cyclophosphamide (Dewidar et al., 2023), and pentoxifylline (Castellanos-Esparza et al., 2018).”
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
“HMGCR expression may also be relevant, given the inverse association with 5-FU sensitivity (Xing et al., 2024).”
Zhou, X., Chen, Y., Hua, H., Shen, B., Liang, S., & Hua, D. (2026) · Drug Development Research · doi:10.1002/ddr.70388
Metadata
- Authors
- Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., Li, Z., Zhao, B., Liu, W., Sun, H., & Yu, Z.
- Affiliations
- Lanzhou University Second Hospital (CN)
- Corresponding author
- Yu, Zeyuan
- ORCID
- Venue
- Medical Oncology
- Published
- 2024-11-20
- Volume
- 42
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1357-0560 (ISSN-L)
- 1559-131X
- PMC
- PMC11579105
- OpenAlex
- W4404540456
- Cited by
- 4
- References
- 42
- Citations by year
- 2026: 3 · 2025: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Medical Oncology (publishedVersion, cc-by-nc-nd)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Cuiying Scientific and Technological Innovation Program (CY2022-MS-A05)
- National Natural Sciences Foundation of China (82360601)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mevalonate pathway, 5-fluorouracil resistance, pancreatic cancer, pyroptosis, gasdermin D, HMGCR, simvastatin, geranylgeranyl pyrophosphate, combination therapy, chemotherapy synergy, tumor organoids
- MeSH terms
- Pyroptosis, Animals, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Female, Fluorouracil, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Mevalonic Acid, Pancreatic Neoplasms, Polyisoprenyl Phosphates, Drug Resistance, Neoplasm, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.